Difference between revisions of "Charles B. Nemeroff"

From Powerbase
Jump to: navigation, search
(New page: {{Template:Pharma_Portal_badge}} '''Charles B. Nemeroff''', M.D., Ph.D., is professor and chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Mille...)
 
(Controversies)
 
(One intermediate revision by the same user not shown)
Line 5: Line 5:
 
==Controversies==
 
==Controversies==
  
[[GlaxoSmithKline]] Payment Disclosures
+
'''[[GlaxoSmithKline]] Payment Disclosures'''
  
 
In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from [[GSK]]. <ref>Goldstein, J.The Wall Street Journal. 3 October 2008. [http://blogs.wsj.com/health/2008/10/03/grassley-says-emory-psychiatrist-didnt-report-500000-in-payments/ Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments] Accessed 3 February 2010.</ref>
 
In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from [[GSK]]. <ref>Goldstein, J.The Wall Street Journal. 3 October 2008. [http://blogs.wsj.com/health/2008/10/03/grassley-says-emory-psychiatrist-didnt-report-500000-in-payments/ Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments] Accessed 3 February 2010.</ref>
 
At the time, he was the main investigator of a collaborative project between Emory University, [[GSK]] and the US government’s [[National Institute of Mental Health]] investigating ‘five novel GSK antidepressants’. <ref>Grassley, C. 2 October 2008. [http://s.wsj.net/public/resources/documents/SenateLetter081003.pdf Senate Letter] Accessed 2 February 2010.</ref>
 
At the time, he was the main investigator of a collaborative project between Emory University, [[GSK]] and the US government’s [[National Institute of Mental Health]] investigating ‘five novel GSK antidepressants’. <ref>Grassley, C. 2 October 2008. [http://s.wsj.net/public/resources/documents/SenateLetter081003.pdf Senate Letter] Accessed 2 February 2010.</ref>
 +
 +
'''[[Cyberonics]] Payment Disclosures'''
 +
 +
In 2006, Nemeroff was the primary author of a paper published in [[Neuropsychopharmacology]] and wrote in 'positive terms' about Vagus Nerve Stimulation - a medical device manufactured by [[Cyberonics]] used for refractory eplipsy and treatment-resistant depression. At the time, he was editor-in-chief of the [[ACNP]] journal and head of the Cyberonics advisory board, but failed to disclose financial ties to the company. The [[ACNP]] accused Nemeroff of operating a "slick public relations disinformation campaign, hiring a
 +
ghostwriter, and incestuously placing the article in his own journal". <ref>McHenry L., (2010), Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. In: Psychopharmacology Today: Some Issues (A.R. Singh and S.A. Singh eds.), MSM, 8, Jan - Dec 2010, p129-145.</ref>
  
 
==Notes==
 
==Notes==

Latest revision as of 21:34, 4 February 2010

Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

Charles B. Nemeroff, M.D., Ph.D., is professor and chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.[1] Previously, he spent 18 years at the Emory University School of Medicine in Atlanta. He is the former Editor-in-Chief of Neuropsychopharmacology, the journal of the American College of Neuropsychopharmacology(ACNP). [2]

Controversies

GlaxoSmithKline Payment Disclosures

In 2008, Nemeroff was accused of failing to disclose $500,000 worth of payments from GSK. [3] At the time, he was the main investigator of a collaborative project between Emory University, GSK and the US government’s National Institute of Mental Health investigating ‘five novel GSK antidepressants’. [4]

Cyberonics Payment Disclosures

In 2006, Nemeroff was the primary author of a paper published in Neuropsychopharmacology and wrote in 'positive terms' about Vagus Nerve Stimulation - a medical device manufactured by Cyberonics used for refractory eplipsy and treatment-resistant depression. At the time, he was editor-in-chief of the ACNP journal and head of the Cyberonics advisory board, but failed to disclose financial ties to the company. The ACNP accused Nemeroff of operating a "slick public relations disinformation campaign, hiring a ghostwriter, and incestuously placing the article in his own journal". [5]

Notes

  1. University of MiamiUM Miller School of Medicine Names New Chair of Psychiatry] Accessed 30 January 2010.
  2. Emory University.Psychiatry: Emory Accessed 2 February 2010.
  3. Goldstein, J.The Wall Street Journal. 3 October 2008. Grassley says Emory Psychiatrist Didnt Report 500,000 in Payments Accessed 3 February 2010.
  4. Grassley, C. 2 October 2008. Senate Letter Accessed 2 February 2010.
  5. McHenry L., (2010), Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. In: Psychopharmacology Today: Some Issues (A.R. Singh and S.A. Singh eds.), MSM, 8, Jan - Dec 2010, p129-145.